Prevalence of hepatitis C virus infection in patients with end-stage renal disease in Latin America and the Caribbean: a systematic review and meta-analysis

Huarez, Bertha; Hernández-Vasquéz, Akram; Azañedo, Diego; Vargas-Fernández, Rodrigo; Comandé, Daniel; Agüero-Palacios, Ysela

doi:10.1007/s00705-022-05604-6

Cited by 4 publications

(2 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another has been conducted in the Middle East and North Africa, Latin America and Caribbean, Asia, and Africa regions [21][22][23][24][25]. A couple of narrative reviews (one on the worldwide magnitude of HCV in HD populations from 1999-2007; the other on HCV transmission in the dialysis setting and prevention strategies) are published [26,27].…”

Section: Introductionmentioning

confidence: 99%

Global epidemiology of hepatitis C virus in dialysis patients: A systematic review and meta-analysis

Kenfack-Momo,

Ngounoue,

Kenmoe

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

Dialysis is a replacement therapy for patients with End-Stage Renal Disease (ESRD). Patients on dialysis are at high risk of acquiring hepatitis C virus (HCV), which has become a leading cause of morbidity and mortality in this population. There is a wide range of prevalence of HCV in dialysis populations around the world. It is still unknown how prevalent HCV infection is among worldwide dialysis patients (including those undergoing hemodialysis and peritoneal dialysis). A review was conducted to estimate the global epidemiology of hepatitis C in dialysis patients. We searched PubMed, Excerpta Medica Database (Embase), Global Index Medicus and Web of Science until October 2022. A manual search of references from relevant articles was also conducted. Heterogeneity was evaluated by the χ2 test on Cochrane’s Q statistic, and the sources of heterogeneity were investigated using subgroup analysis. In order to assess publication bias, funnel plots and Egger tests were conducted, and pooled HCV prevalence estimates were generated using a DerSimonian and Laird meta-analysis model. The study is registered with PROSPERO under CRD42022237789. We included 634 papers involving 392160 participants. The overall HCV case fatality rate was 38.7% (95% CI = 28.9–49). The global prevalence of HCV infection in dialysis population group were 24.3% [95% CI = 22.6–25.9]. As indicated by UNSD region, country, dialysis type, and HCV diagnostic targeted; Eastern Europe had the highest prevalence of 48.6% [95% CI = 35.2–62], Indonesia had 63.6% [95% CI = 42.9–82], hemodialysis patients had 25.5% [95% CI = 23.8–27.3], and anti-HCV were detected in 24.5% [95% CI = 22.8–26.2]. Dialysis patients, particularly those on hemodialysis, have a high prevalence and case fatality rate of HCV infection. Hemodialysis units need to implement strict infection control measures.

show abstract

Section: Introductionmentioning

confidence: 99%

Global epidemiology of hepatitis C virus in dialysis patients: A systematic review and meta-analysis

Kenfack-Momo,

Ngounoue,

Kenmoe

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…5 In 2016, chronic kidney disease (CKD) impacted more than 275 million people worldwide, with an incidence of over 21 million new cases, over 1 million deaths, and over 35 million disability-adjusted life years (showing an increase in prevalence of 87.8% over the previous three decades). 6 The prevalence of HCV infection among hemodialysis (HD) recipients varies by country as well as by facility within the same country. Egypt is one of the nations with the highest prevalence of HCV disease despite the existence of infection control program criteria.…”

Section: Introductionmentioning

confidence: 99%

The burden of HCV among prevalent hemodialysis patients after the National Egyptian HCV Eradication program

Hendam

2024

EJI

View full text Add to dashboard Cite

In the first phase of its treatment program, Egypt aimed to treat 250,000 people annually until 2020, thereby reducing the number of viremic patients and limiting hepatitis C virus (HCV) transmission. Egypt strives to eradicate HCV and HCV-associated morbidity by 2030. This study aimed to determine the prevalence of HCV infection among end-stage renal disease patients and the reasons for non-treatment among those offered free medication. This multi-center cross-sectional study was conducted during the period from November 2022 to April 2023. The study included 500 patients receiving hemodialysis (HD) sessions on a regular basis for more than three months in Dakahlia Governorate. According to patients` medical history, we found that 23.4% of patients had previous HCV infection. Of these, 12.6% received treatment, and 10.8% did not receive treatment due to a variety of reasons. For instance, some patients were unaware of the drug’s availability, five patients (1%) feared side effects, 43 patients (8.6%) did not require treatment, and five patients (1%) had other causes as contraindications of drugs, noncompliance and deterioration of health status. In addition, 20.4% of patients were reported to have fully recovered, while 0.8% had a recurrence. After investigations, 1% of patients had positive hepatitis B surface antigen (HbsAg), 23.4% positive HCV Ab, and 4.2% positive HCV by the polymerase chain reaction. In conclusion, the low prevalence of HCV among HD patients confirms that HCV infection is not currently a significant health concern among patients on maintenance HD.

show abstract

Hepatitis C and hepatocellular carcinoma in Latin America: Elimination as a path to cancer prevention

Goble,

Mattos,

Mendizabal

et al. 2023

Annals of Hepatology

View full text Add to dashboard Cite

Prevalence of hepatitis C virus infection in patients with end-stage renal disease in Latin America and the Caribbean: a systematic review and meta-analysis

Cited by 4 publications

References 45 publications

Global epidemiology of hepatitis C virus in dialysis patients: A systematic review and meta-analysis

Global epidemiology of hepatitis C virus in dialysis patients: A systematic review and meta-analysis

The burden of HCV among prevalent hemodialysis patients after the National Egyptian HCV Eradication program

Hepatitis C and hepatocellular carcinoma in Latin America: Elimination as a path to cancer prevention

Contact Info

Product

Resources

About